Virax Biolabs announces 1-for-25 reverse stock split on Nasdaq

Virax Biolabs Group Limited (NASDAQ: VRAX) announced a 1-for-25 share consolidation of its ordinary shares, effective June 26, 2026, according to a press release from the London-based biotechnology company.

The company's board of directors approved the consolidation after shareholders voted in favor of the measure at an adjourned extraordinary general meeting held June 12, 2026, in Newhouse, Lanarkshire, Scotland.

Beginning at the open of trading on June 26, 2026, the shares will trade on the Nasdaq Capital Market under the existing ticker symbol "VRAX" but with a new CUSIP number of G9495L133.

Under the terms of the consolidation, every 25 issued and outstanding ordinary shares with a par value of $0.001 each will be automatically converted into one ordinary share with a par value of $0.025. No fractional shares will be issued; any fractional entitlements will be rounded up to the next whole share.

The company stated the consolidation is intended to regain compliance with Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of at least $1 per share. The consolidation will affect all shareholders uniformly and will not alter any shareholder's percentage interest in the company, except for adjustments resulting from the treatment of fractional shares.

Virax Biolabs has filed a fourth Amended and Restated Memorandum and Articles of Association reflecting the change with the Cayman Islands Registrar of Companies.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• Berenberg Starts Bridgepoint Group PLC (BPT:LN) at Buy
• Virginia National Bankshares Corporation. (VABK) Tops Q2 EPS by 165c